Provided by Tiger Trade Technology Pte. Ltd.

Arrowhead Pharmaceuticals

57.78
-2.9900-4.92%
Post-market: 57.780.00000.00%19:10 EDT
Volume:1.65M
Turnover:96.29M
Market Cap:8.09B
PE:39.17
High:61.48
Open:60.29
Low:57.58
Close:60.77
52wk High:76.76
52wk Low:9.57
Shares:140.01M
Float Shares:120.00M
Volume Ratio:0.51
T/O Rate:1.38%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.48
EPS(LYR):-0.0122
ROE:75.50%
ROA:14.35%
PB:14.23
PE(LYR):-4,738.78

Loading ...

Arrowhead price target raised to $48 from $45 at Morgan Stanley

TIPRANKS
·
Nov 26, 2025

Arrowhead Pharmaceuticals: Promising Growth with Redemplo Launch and Strategic Developments in Obesity Treatments

TIPRANKS
·
Nov 26, 2025

Arrowhead Pharma Q4 EPS $(0.09) Beats $(0.29) Estimate, Sales $256.478M Beat $175.862M Estimate

Benzinga
·
Nov 26, 2025

Arrowhead Pharmaceuticals FY25 EPS $(0.01) Up From $(5.00) YoY; Revenue $829.448M Up From $3.551M YoY

Benzinga
·
Nov 26, 2025

Press Release: Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results

Dow Jones
·
Nov 26, 2025

Arrowhead options imply 11.3% move in share price post-earnings

TIPRANKS
·
Nov 26, 2025

Stock Track | Arrowhead Pharmaceuticals Soars 5% on $200 Million Payment from Sarepta and Upcoming Earnings

Stock Track
·
Nov 26, 2025

Stock Track | Arrowhead Pharmaceuticals Soars 5.02% on $200 Million Milestone Payment from Sarepta

Stock Track
·
Nov 26, 2025

Arrowhead Pharmaceuticals (ARWR) Receives a Buy from B. Riley Securities

TIPRANKS
·
Nov 25, 2025

Top News Today/Canada: Barrick Makes a Deal With Mali

Dow Jones
·
Nov 25, 2025

Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics

Reuters
·
Nov 24, 2025

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Nov 24, 2025

Arrowhead Pharmaceuticals Is Maintained at Neutral by Goldman Sachs

Dow Jones
·
Nov 20, 2025

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Nov 20, 2025

Arrowhead price target raised to $48 from $27 at Goldman Sachs

TIPRANKS
·
Nov 20, 2025

Arrowhead Pharmaceuticals Poised for Commercial Transition After First FDA Approval, RBC Says

MT Newswires Live
·
Nov 20, 2025

RBC Raises Price Target on Arrowhead Pharmaceuticals to $52 From $45, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Nov 19, 2025

Arrowhead Pharmaceuticals Is Maintained at Overweight by Piper Sandler

Dow Jones
·
Nov 19, 2025

Arrowhead Pharmaceuticals (ARWR) Receives a Buy from RBC Capital

TIPRANKS
·
Nov 19, 2025

Arrowhead Pharmaceuticals: Hold Rating Amid Market Challenges and Future Opportunities

TIPRANKS
·
Nov 19, 2025